|
|
Post by lorcan458 on Nov 18, 2015 8:00:58 GMT -5
I'm a long investor, in at 5.92. I haven't sold a single share and won't for under $25. My MNKD shares are in my risky IRA. I have index funds for the money I am truly counting on for retirement. Here's the letter I sent to Matt this morning. If he responds to one or more of the questions, I will share unless he specifically asks me not to or there is non-disclosure statement on the response.
Matt,
I’m one of your many faithful, but very perplexed, and very underwater investors. There are some very straightforward questions that never seem to be directly addressed. I know you may not have the time to address me directly, but I want you to know what we investors are wanting to know.
1. Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list?
2. Why doesn’t Al Mann put an end to bankruptcy speculation by a quick press release:
“I’ve invested well over a billion dollars bringing this revolutionary drug to diabetics. I will not let outside forces who are afraid of this revolution to put the financing of Mannkind at risk.”
3. Why don’t you ask Sanofi to release a one line statement to the press:
“We are fully behind Afrezza. It is a core component of our future plans. Television commercials will commence as soon as xx% of insurance providers provide tier 2 coverage. We are working on a label change, which will happen soon. We are working on a superiority study which will start on (date) and include a double-blind study with (x) patients.”
4. Our pain medication trials with (partner) will begin on (date).
5. Our pulmonary hypertension trials with (partner) will begin on (date).
6. Alphabet will be providing contact lens based realtime glucose monitoring, a health tracker phone application and we will provide a smart dosage inhaler to completely revolutionize management of diabetes.
7. TEVA will be testing (x) new generic drugs delivered via Technosphere. Trials will begin on (date).
8. Sanofi has (x) number of sales reps visiting (x) number of doctors a week.
9. The reason scripts have inexplicably remained near 500 is (x). This number will grow immediately because of (x) and (x) and (x).
|
|
|
|
Post by peppy on Nov 18, 2015 8:41:48 GMT -5
My read is; Inappropriate letter.
quote;
Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list?
reply: What is he supposed to do about it?
|
|
|
|
Post by mssciguy on Nov 18, 2015 8:51:46 GMT -5
My read is; Inappropriate letter. quote; Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list? reply: What is he supposed to do about it? I believe that SEC is aware of the naked shorting/manipulation of MNKD stock. The best thing an individual can do is call and write SEC early and often to report suspected manipulation and/or losses. It's clear from other message boards that reports from retail holders are streaming into SEC by the dozen on a weekly (if not daily) basis. There's a lot of destruction out there thanks to the "hedgies" (what a cute name for greedy, relentless and destructive forces out for short term gain at any cost). (Look at SUNE recently-- how could a company go from hedge fund darling to a 90% drop in just a couple of months? How could they be that wrong? What changed? ) This is a very scary market thanks to algorithms, HFT, and hedge fund secrecy. Let's hope some heads roll, eventually. MNKD manipulation may be small potatoes to SEC at this time, but if we all are vocal, maybe the duration of manipulation will be shorter than it otherwise would have been. Thank you all who have also taken the time to contact SEC. |
|
|
|
Post by vissertrades on Nov 18, 2015 8:53:10 GMT -5
Let Management work through the current headwinds as they have a product that produces non-diabetic numbers in a huge market (Billions at stake). What other product can do this? Forces and pressures against this new product are obvious and "they" don't want it to gain traction and are attempting to do whatever "they" can to distrupt progress as this IS by definition - distruptive technology.
|
|
|
|
Post by mssciguy on Nov 18, 2015 9:04:11 GMT -5
lorcan458 There is a really cool idea floating around stocktwits mnkd board right now about how you can support Afrezza: Submit the videos of Afrezza coverage on various local news stations, to your local TV/newspaper contacts. The news business cross-fertilizes with affiliates in other cities a lot, this might actually work.... think of the hundreds of thousands of viewers! Just an idea. I can't do it myself, because I live in company town that would not think of supporting a Sanofi product, but maybe you could? Have a great day, but I agree that mgmt is firing on all cylinders and is bound by confidentiality agreements although we all crave some information..
|
|
|
|
Post by kbrion77 on Nov 18, 2015 9:13:59 GMT -5
I'm a long investor, in at 5.92. I haven't sold a single share and won't for under $25. My MNKD shares are in my risky IRA. I have index funds for the money I am truly counting on for retirement. Here's the letter I sent to Matt this morning. If he responds to one or more of the questions, I will share unless he specifically asks me not to or there is non-disclosure statement on the response. Matt, I’m one of your many faithful, but very perplexed, and very underwater investors. There are some very straightforward questions that never seem to be directly addressed. I know you may not have the time to address me directly, but I want you to know what we investors are wanting to know. 1. Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list? 2. Why doesn’t Al Mann put an end to bankruptcy speculation by a quick press release: “I’ve invested well over a billion dollars bringing this revolutionary drug to diabetics. I will not let outside forces who are afraid of this revolution to put the financing of Mannkind at risk.” 3. Why don’t you ask Sanofi to release a one line statement to the press: “We are fully behind Afrezza. It is a core component of our future plans. Television commercials will commence as soon as xx% of insurance providers provide tier 2 coverage. We are working on a label change, which will happen soon. We are working on a superiority study which will start on (date) and include a double-blind study with (x) patients.” 4. Our pain medication trials with (partner) will begin on (date).5. Our pulmonary hypertension trials with (partner) will begin on (date). 6. Alphabet will be providing contact lens based realtime glucose monitoring, a health tracker phone application and we will provide a smart dosage inhaler to completely revolutionize management of diabetes. 7. TEVA will be testing (x) new generic drugs delivered via Technosphere. Trials will begin on (date).8. Sanofi has (x) number of sales reps visiting (x) number of doctors a week. 9. The reason scripts have inexplicably remained near 500 is (x). This number will grow immediately because of (x) and (x) and (x). No Senior Manager for any company would put themselves on the hook for these statements regarding business development. |
|
|
|
Post by bradleysbest on Nov 18, 2015 9:23:00 GMT -5
It's more like a cry for help from MNKD management. We are taking it in the "shorts", pun intended. Please Matt give us something, anything that gives us hope you and SNY are looking out for our financial future! Oh well, I continue to believe in Al & the science of Afrezza & will hold all my shares until I am wealthy or flat out broke.......
PS .. I know a few people who bought in around $18 a share! OUCH
|
|
|
|
Post by lorcan458 on Nov 18, 2015 9:26:16 GMT -5
Release a statement:
"Our legal department has an open investigation with the SEC, case number 325424xxxx that addresses the repeated pattern of negative articles, HFT trading and most importantly the Failed to Deliver shares."
|
|
|
|
Post by lorcan458 on Nov 18, 2015 9:26:56 GMT -5
Release a statement: "Our legal department has an open investigation with the SEC, case number 325424xxxx that addresses the repeated pattern of negative articles, HFT trading and most importantly the Failed to Deliver shares." Sorry, that was to peppy. I hit reply instead of quote. |
|
|
|
Post by lorcan458 on Nov 18, 2015 9:33:50 GMT -5
4. Our pain medication trials with (partner) will begin on (date).5. Our pulmonary hypertension trials with (partner) will begin on (date). 6. Alphabet will be providing contact lens based realtime glucose monitoring, a health tracker phone application and we will provide a smart dosage inhaler to completely revolutionize management of diabetes. 7. TEVA will be testing (x) new generic drugs delivered via Technosphere. Trials will begin on (date). No Senior Manager for any company would put themselves on the hook for these statements regarding business development. Medicine is not a consumer product where you can have secrecy followed by a launch in a retail store the next day. These public, government-registered trials will take months to years. Releasing this information will not give a competitive advantage if the trials are ready to begin within a few months. What I'm really asking for is for management to get specific about the pipeline. Every other biotech stock I have has a pipeline listing specific drugs, what stage they are in for trials and how long (usually a couple of years) the process will take. A press release about this type of information and an updated website with the full pipeline is the industry norm. |
|
|
|
Post by lorcan458 on Nov 18, 2015 10:27:17 GMT -5
Upon reflection, I was a bit too emotional in my letter. Let's see if we can come up with a doable list of goals for management to accomplish:
1. Get Sanofi to publicly state that Afrezza is fully supported and a core component of their future strategy in the years to come.
2. Get Sanofi to acknowledge that their partnership with Alphabet includes an Afrezza component.
3. Confirm that the SEC is actively looking into illegal trading resulting in Failed to Deliver shares.
4. Publish an industry standard pipeline on their (finally) complete up to date website.
5. If the only thing holding back TV commercials is insurance coverage levels, let us know. If we're waiting for a label change, let us know.
|
|
|
|
Post by BlueCat on Nov 18, 2015 10:49:40 GMT -5
Upon reflection, I was a bit too emotional in my letter. Let's see if we can come up with a doable list of goals for management to accomplish: 1. Get Sanofi to publicly state that Afrezza is fully supported and a core component of their future strategy in the years to come. 2. Get Sanofi to acknowledge that their partnership with Alphabet includes an Afrezza component. 3. Confirm that the SEC is actively looking into illegal trading resulting in Failed to Deliver shares. 4. Publish an industry standard pipeline on their (finally) complete up to date website. 5. If the only thing holding back TV commercials is insurance coverage levels, let us know. If we're waiting for a label change, let us know. Better, but still trying to make them commit to things they would be legally advised against ... I think however, there would be nothing stopping Old Mann from reiterating his financial long term support (as well as that of his Foundation) more clearly, as well as SNY making an unambiguous statement of sorts. (We are committed to a long, and ongoing fruitful relationship with MNKD …. er, whatever form that may take). This would squash the financial FUD based on uncertainty - including the question of financial transition/leadership when that unfortunate day arrives. #2 would be exposing too much SNY strategy. #3 I think Matt/Hakan have said all they can. #4 can't commit until signed in blood. #5 I think they have explained their strategy here, albeit not with the most direct of communication style. |
|
|
|
Post by BlueCat on Nov 18, 2015 10:50:33 GMT -5
My read is; Inappropriate letter. quote; Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list? reply: What is he supposed to do about it? I believe that SEC is aware of the naked shorting/manipulation of MNKD stock. The best thing an individual can do is call and write SEC early and often to report suspected manipulation and/or losses. It's clear from other message boards that reports from retail holders are streaming into SEC by the dozen on a weekly (if not daily) basis. There's a lot of destruction out there thanks to the "hedgies" (what a cute name for greedy, relentless and destructive forces out for short term gain at any cost). (Look at SUNE recently-- how could a company go from hedge fund darling to a 90% drop in just a couple of months? How could they be that wrong? What changed? ) This is a very scary market thanks to algorithms, HFT, and hedge fund secrecy. Let's hope some heads roll, eventually. MNKD manipulation may be small potatoes to SEC at this time, but if we all are vocal, maybe the duration of manipulation will be shorter than it otherwise would have been. Thank you all who have also taken the time to contact SEC. Squeaky Wheel. |
|
|
|
Post by compound26 on Nov 18, 2015 10:52:36 GMT -5
lorcan458 There is a really cool idea floating around stocktwits mnkd board right now about how you can support Afrezza: Submit the videos of Afrezza coverage on various local news stations, to your local TV/newspaper contacts. The news business cross-fertilizes with affiliates in other cities a lot, this might actually work.... think of the hundreds of thousands of viewers! Just an idea. I can't do it myself, because I live in company town that would not think of supporting a Sanofi product, but maybe you could? Have a great day, but I agree that mgmt is firing on all cylinders and is bound by confidentiality agreements although we all crave some information.. mssciguy, great idea. For anyone interested, the following links may be helpful to you (just added a new link to Afrezza_just breathe Youtube channel): www.afrezzajustbreathe.com/tv-news-report-on-afrezza/www.afrezzajustbreathe.com/videos-of-afrezza-users/www.youtube.com/channel/UCylbMp5M3Ybt_GcavDQzArA/featured |
|
|
|
Post by silentknight on Nov 18, 2015 11:18:44 GMT -5
I'm a long investor, in at 5.92. I haven't sold a single share and won't for under $25. My MNKD shares are in my risky IRA. I have index funds for the money I am truly counting on for retirement. Here's the letter I sent to Matt this morning. If he responds to one or more of the questions, I will share unless he specifically asks me not to or there is non-disclosure statement on the response. Matt, I’m one of your many faithful, but very perplexed, and very underwater investors. There are some very straightforward questions that never seem to be directly addressed. I know you may not have the time to address me directly, but I want you to know what we investors are wanting to know. 1. Why do you allow the endless stream of co-ordinated hit-articles from Motley Fool & Adam F. to be quickly followed by HFT to drive the price down when your stock is constaintly on the Failed to Deliver list? 2. Why doesn’t Al Mann put an end to bankruptcy speculation by a quick press release: “I’ve invested well over a billion dollars bringing this revolutionary drug to diabetics. I will not let outside forces who are afraid of this revolution to put the financing of Mannkind at risk.” 3. Why don’t you ask Sanofi to release a one line statement to the press: “We are fully behind Afrezza. It is a core component of our future plans. Television commercials will commence as soon as xx% of insurance providers provide tier 2 coverage. We are working on a label change, which will happen soon. We are working on a superiority study which will start on (date) and include a double-blind study with (x) patients.” 4. Our pain medication trials with (partner) will begin on (date). 5. Our pulmonary hypertension trials with (partner) will begin on (date). 6. Alphabet will be providing contact lens based realtime glucose monitoring, a health tracker phone application and we will provide a smart dosage inhaler to completely revolutionize management of diabetes. 7. TEVA will be testing (x) new generic drugs delivered via Technosphere. Trials will begin on (date). 8. Sanofi has (x) number of sales reps visiting (x) number of doctors a week. 9. The reason scripts have inexplicably remained near 500 is (x). This number will grow immediately because of (x) and (x) and (x). These are all questions that we want answers to and the resolute silence from MNKD management on them all is frustrating to say the least. From company financing to product development, and most things in between, the past few years has been fraught with examples of management "mis-speaking" that has led to a punishing response from the market to the stock price. These are legitimate questions and to be honest, I'm beginning to think neither Matt nor Hakan has answers to any of them that would do much to stop the bleeding. Perhaps they can't speak to SNY's Afrezza strategy with studies and label improvements, but I've never signed an NDA or seen one that prohibited anyone from saying something to the effect of "Stipulations of our current agreement prohibit us from speaking to that issue." It wouldn't do much but it would refute the notion from many naysayers that MNKD management is asleep at the wheel as the company slowly dies. As time goes on and we continue to hear nothing, it lends more credence to whatever doubts exist about their effectiveness and suitability for their jobs. I think there is probably some strategy in place. I sincerely hope there and I'm holding in the hopes that it pays off but management needs to step it up if the company, and its shareholders, are to weather this storm. Communication is a large part of that and in communicating with both shareholders and analysts in the conference calls and presentations, current leadership has failed. |
|
